Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Wake Forest University Health Sciences
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05408910CT.gov Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cystic Fibrosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rifaximin (this asset) | Wake Forest University Health Sciences | P2/3 | CCC · 52 |
| Tezacaftor | Vertex Pharmaceuticals Incorporated | P4 | A |
| Lumacaftor | Hospices Civils de Lyon | P4 | BBB |
| Ivacaftor | Meyer Children's Hospital IRCCS | P4 | BBB |
| Liprotamase | Anthera Pharmaceuticals | P4 | BBB |
| Elexacaftor | Meyer Children's Hospital IRCCS | P4 | BBB |
| vx-121 | Vertex Pharmaceuticals Incorporated | P3 | BBB |
| Colistin | Liverpool Heart and Chest Hospital NHS Foundation Trust | P4 | BBB |
| Azithromycin | Hospices Civils de Lyon | P4 | BBB |
+42 more in the Cystic Fibrosis cohort
Other indications for Rifaximin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatic Encephalopathy | — | P4 | BBB · 75 |
| Cirrhosis Of Liver | — | P4 | BBB · 72 |
| Hepatitis C Virus Infection | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rifaximin in Cystic Fibrosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rifaximin-cystic-fibrosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →